Cullen/Frost Bankers’s Sarepta Therapeutics SRPT Stock Holding History

Cullen/Frost Bankers’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-16	Closed	-$2.53K	–	1368
2024 Q2	$2.53K	Buy	+16	New	+$2.06K	﹤0.01%	1078
2023 Q3	–	Sell	-300	Closed	-$34.4K	–	1198
2023 Q2	$34.4K	Sell	300 -100	-25%	-$12.9K	﹤0.01%	788
2023 Q1	$55.1K	Hold	400	–	–	﹤0.01%	701
2022 Q4	$51.8K	Hold	400	–	–	﹤0.01%	695
2022 Q3	$44K	Buy	+400	New	+$40.3K	﹤0.01%	725
2020 Q4	–	Sell	-5	Closed	-$1K	–	1178
2020 Q3	$1K	Buy	+5	New	+$760	﹤0.01%	1124

Other funds holding SRPT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Cullen/Frost Bankers's SRPT Position: Q3 2024 in Review

Cullen/Frost Bankers sold out of Sarepta Therapeutics (SRPT) in Q3 2024, closing a stake of 16 shares — an estimated $2.53K sold.

Cullen/Frost Bankers first reported a position in SRPT in Q3 2020 and held it in 6 quarters. The position peaked at $55.1K in Q1 2023. 458 funds tracked by Wall St. Rank hold SRPT as of Q3 2024.

Cullen/Frost Bankers reported no remaining Sarepta Therapeutics position as of Q3 2024 after selling out during the quarter.
Cullen/Frost Bankers sold 16 Sarepta Therapeutics shares in Q3 2024, an estimated $2.53K.
Cullen/Frost Bankers first reported a position in Sarepta Therapeutics in Q3 2020 and held it in 6 quarters.
Cullen/Frost Bankers's Sarepta Therapeutics position peaked at $55.1K in Q1 2023.
458 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q3 2024.

Based on Cullen/Frost Bankers's 13F filing for Q3 2024, filed 6 Nov 2024.